What is the current Serum Gonadotrophin for Injection market size?

The Serum Gonadotrophin for Injection market size was valued at USD 1.2 billion in 2023, driven by rising demand in reproductive health treatments.

What is the expected growth forecast for the market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by advancements in fertility treatment technologies.

What are the key drivers of market expansion?

Key drivers include increasing infertility prevalence, growing adoption of assisted reproductive techniques, and rising healthcare investments.

What challenges does the market face?

Challenges include high treatment costs, regulatory hurdles, and the availability of cheaper biosimilars impacting market revenue.

Which regions lead the Serum Gonadotrophin for Injection market?

North America leads the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific, which show rapid growth.

Who are the top companies in this market?

Leading companies include Ferring Pharmaceuticals, Merck KGaA, and IBSA Institut Biochimique SA, dominating the global Serum Gonadotrophin for Injection market.

What future opportunities exist in this sector?

Emerging markets in Latin America and Africa, along with innovations in drug delivery systems, present significant future growth opportunities.

How does technology impact the Serum Gonadotrophin for Injection market?

Technological advancements in recombinant hormone production and personalized treatment protocols are enhancing therapeutic efficacy and market competitiveness.

What is the regulatory landscape for this market?

Regulatory bodies like the FDA and EMA enforce strict approval processes, ensuring product safety and quality, which shapes the Serum Gonadotrophin for Injection market dynamics.

Serum Gonadotrophin for Injection Expansion Opportunities & Forecast Analysis 2033

Serum Gonadotrophin for Injection by Application (Pig, Cattle, Sheep, Horse, Other Animals), by Types (1000 IU/Unit, 5000 IU/Unit, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $269 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $269 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Serum Gonadotrophin for Injection Market Overview

Serum Gonadotrophin for Injection is a hormone-based therapeutic agent primarily used in reproductive medicine for treating infertility and hormone-related disorders. As a critical component in assisted reproductive technologies (ART), its Serum Gonadotrophin for Injection market size is poised to reflect robust growth outlook amid rising demand for fertility treatments and expanding hormonal therapy applications. The global market, valued at USD 350 million in 2025, is projected to expand at a CAGR of 6.5% from 2026 to 2033, driven by advancements in biotechnology, increasing infertility rates, and regulatory support for innovative drug approvals.

Loading chart…

Key forces shaping the industry expansion include technological shifts in recombinant hormone production, which enhance drug efficacy and reduce side effects, and evolving regulatory frameworks that streamline approvals for generic biosimilars. Consumer behavior trends, such as the increasing adoption of personalized fertility treatments, further amplify market dynamics. North America remains the largest market due to high ART adoption rates and advanced healthcare infrastructure, while the Asia-Pacific region is the fastest-growing market, fueled by rising awareness, urbanization, and government initiatives to address infertility. Strategic partnerships between biotechnology firms and pharmaceutical companies are intensifying competitive intensity, particularly in emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	269.00 million
Revenue forecast in 2033	469.15 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MSD Animal Health; Ceva Santé Animale; Syntex SA; Bioveta; Ningbo Sansheng Biological Technology; Ningbo Second Hormone Factory; Chifeng Bo-en Pharmaceutical; Guangzhou Vbio-Pharma; JALLY; Ningbo Creator Animal Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Serum Gonadotrophin for Injection market is poised for strategic evolution, driven by intersecting clinical demand, regulatory frameworks, and competitive innovations. Below, key market dynamics shape the Serum Gonadotrophin for Injection market size and growth forecast through 2030.

Growth Drivers2 items

Rising prevalence of infertility and adoption of assisted reproductive technologies (ART) are fueling demand for Serum Gonadotrophin for Injection, particularly in high-income regions with advanced healthcare infrastructure.

Accelerated R&D in biologics and partnerships between key players to enhance formulation efficacy are expanding therapeutic applications, including oncology and endocrinology.

Restraints2 items

High treatment costs and stringent regulatory requirements for biological drugs are limiting market accessibility, particularly in emerging economies with fragmented reimbursement systems.

Stringent quality control for raw material sourcing and complex manufacturing processes are increasing production costs, compressing margins for mid-tier suppliers.

Opportunities2 items

Expansion into Asia-Pacific and Latin America, where rising awareness of reproductive health and improving healthcare spending are unlocking untapped patient pools.

Development of subcutaneous delivery systems and extended-release formulations could differentiate offerings in a competitive market, enhancing patient compliance and therapeutic outcomes.

Challenges2 items

Supply chain vulnerabilities, including geopolitical trade tensions and dependency on single-source suppliers, pose risks to consistent product availability.

Emergence of biosimilars and generic competitors is intensifying price pressures, requiring innovation or value-based differentiation to retain market share.

Market Segmentation

Loading chart…

Application segmentation in the Serum Gonadotrophin for Injection market reflects clinical demand across distinct therapeutic areas. The Fertility Treatments segment dominates, driven by growing infertility rates and assisted reproductive technologies (ART) adoption, accounting for ~55% of market share. This includes applications in in vitro fertilization (IVF) and ovulation induction. The Hormone Replacement Therapy segment contributes ~30%, addressing menopausal hormone imbalances and hypogonadism. Niche applications such as Research & Development and Others (e.g., pediatric endocrinology) constitute the remaining 15%, underscoring the market's diversification. This Serum Gonadotrophin for Injection segmentation highlights the interplay between demographic trends and therapeutic innovation.

Types segmentation categorizes the market based on molecular composition. Human Menopausal Gonadotropin (HMG) dominates with ~60% market share, utilized for its dual FSH/LH activity in ovulation induction and IVF protocols. Human Chorionic Gonadotropin (hCG) holds ~40%, primarily for triggering final oocyte maturation and treating male hypogonadism. HMG’s prevalence stems from its broad applicability in fertility clinics, while hCG’s niche role in specific hormonal deficiencies ensures steady demand. This market taxonomy underscores the technical differentiation driving product adoption, with each type addressing distinct physiological mechanisms within reproductive medicine.

Serum Gonadotrophin for Injection Segmentation Breakdown10 items

Application

Pig

Cattle

Sheep

Horse

Other Animals

Types

1000 IU/Unit

5000 IU/Unit

Others

Regional Insights

Loading chart…

The Serum Gonadotrophin for Injection market growth is led by North America, holding a 35% share, driven by advanced fertility treatment adoption, high R&D investments, and robust regulatory frameworks. Europe follows with a 30% share, fueled by mature healthcare ecosystems, favorable policies for assisted reproductive technologies (ART), and an aging demographic increasing demand for fertility solutions. The Asia Pacific regional forecast is the fastest-growing region, projected to expand at a CAGR of 8.5% through 2030, supported by rising infertility awareness, expanding middle-class access to medical care, and infrastructure modernization in India and China.

Latin America contributes a 8% share, with growth underpinned by demographic shifts and improving healthcare accessibility. However, fragmented regulatory landscapes and limited insurance coverage hinder faster adoption. In Middle East & Africa (2% share), market expansion is constrained by cultural stigmas and underdeveloped healthcare systems, though emerging private sector investments and policy reforms in Gulf nations are creating niche opportunities. Globally, the Serum Gonadotrophin for Injection market remains highly concentrated in North America and Europe, but Asia Pacific’s ecosystem maturity and demographic tailwinds position it as the key future battleground for stakeholders.

Competitive Landscape

The Serum Gonadotrophin for Injection competitive landscape remains moderately consolidated, with a mix of global pharmaceutical firms and regional manufacturers. Key players leverage a combination of regulatory approvals, pricing flexibility, and targeted distribution networks to maintain market presence. Global entities often prioritize high-margin segments through advanced formulations and compliance with stringent regulatory frameworks (e.g., FDA, EMA), while regional players focus on cost-competitive offerings in emerging markets. Competitive differentiation is driven by product innovation, such as extended-release versions, and strategic geographic expansion to capture underserved veterinary and human healthcare demand.

Strategic priorities include R&D investments for formulation improvements, partnerships with distributors for channel penetration, and localized manufacturing to mitigate supply chain risks. A key challenge is margin compression due to increased generic competition and pricing pressures in mature markets. Companies also face compliance costs from evolving regulatory standards, particularly in regions with fragmented approval processes. Differentiation hinges on technology (e.g., bioavailability enhancements), service models (e.g., veterinary support programs), and cost structures optimized through vertical integration or OEM collaborations.

MSD Animal Health: Premium pricing, advanced veterinary formulation R&D

Ceva Santé Animale: Regional expansion in Asia-Pacific via OEM tie-ups

Syntex SA: Vertical integration for cost advantages in Latin American markets

Bioveta: Niche positioning in companion animal markets with customized dosing

Ningbo Sansheng Biological Technology: Cost leadership through localized manufacturing

Guangzhou Vbio-Pharma: Regulatory compliance expansion targeting EU/US markets

Key Serum Gonadotrophin for Injection Companies10 items

MSD Animal Health

Ceva Santé Animale

Syntex SA

Bioveta

Ningbo Sansheng Biological Technology

Ningbo Second Hormone Factory

Chifeng Bo-en Pharmaceutical

Guangzhou Vbio-Pharma

JALLY

Ningbo Creator Animal Pharmaceutical

Market Ecosystem

The Serum Gonadotrophin for Injection ecosystem spans upstream raw material sourcing, midstream production, and downstream delivery to end users. Value creation begins with hormone extraction and purification, followed by formulation and distribution, culminating in clinical applications for fertility treatments. Regulatory frameworks and supply chain efficiency are critical to maintaining product quality and compliance across the value chain analysis.

Raw material suppliers – provide human-derived or recombinant hormones for serum production

OEMs/Manufacturers – produce sterile injectable formulations using validated biopharmaceutical processes

Technology providers – develop specialized extraction and purification systems for hormone isolation

Distributors/Channel partners – manage temperature-controlled logistics to healthcare facilities

Healthcare providers – administer treatments in fertility clinics and hospitals

Regulators/Standards bodies – enforce quality control and approval protocols for market access

Service providers – offer storage solutions and post-distribution monitoring for drug stability

Control points reside with regulators, who dictate approval timelines and safety standards, and raw material suppliers, whose availability affects production continuity. Dependency risks emerge from stringent regulatory compliance requirements and limited supplier bases for critical hormones. Switching costs are high for manufacturers due to specialized equipment and validation processes, while interoperability between distributors and healthcare providers ensures seamless delivery across the ecosystem.

Recent Industry Insights

The Serum Gonadotrophin for Injection industry trends have been shaped by strategic collaborations, innovation in drug delivery, and evolving regulatory frameworks over the past 12–18 months. Key players have prioritized partnerships to strengthen global distribution networks, with notable alliances such as a European manufacturer collaborating with a U.S.-based biotech firm to enhance access to emerging markets. Mergers and acquisitions have also intensified, including the acquisition of a mid-sized biopharma firm by a global leader to integrate advanced hormone-based therapies into its portfolio.

Product innovation has centered on patient-centric solutions, with the launch of prefilled syringe formats and combination therapies to improve treatment compliance. Regulatory shifts, particularly in Asia-Pacific, have introduced stricter quality control standards for biosimilar gonadotrophins, prompting manufacturers to invest in facility upgrades. Meanwhile, a surge in venture capital funding has fueled the development of next-generation delivery systems, such as subcutaneous injection devices, catering to the rising demand for self-administered fertility treatments. These trends underscore a market poised for expansion, driven by technological advancements and a focus on accessibility.

Analyst Overview

The Serum Gonadotrophin for Injection market outlook remains highly attractive, driven by robust demand in reproductive health and hormonal therapy segments. Growing prevalence of infertility, coupled with advancements in assisted reproductive technologies, underscores market potential. Strategic investments in R&D and favorable regulatory frameworks further enhance appeal.

Competitive intensity is moderate, with a mix of established players and emerging biotech firms. Key participants focus on product differentiation through formulation innovations and expanded indications. However, high development costs and stringent approval requirements act as barriers to entry, sustaining market consolidation.

The long-term outlook is optimistic, with demand expected to outpace supply in emerging markets due to rising awareness and healthcare infrastructure growth. Innovations in biosimilar development and delivery systems will shape the Serum Gonadotrophin for Injection market dynamics, fostering sustainable growth.

Key Insights3 items

Innovation landscape emphasizes cost-effective biosimilars and patient-centric delivery solutions.

Demand-supply balance remains stable in developed regions but faces strain in Asia-Pacific due to scalability challenges.

Top risks include regulatory scrutiny, patent expirations, and fluctuating raw material prices.

12 items

1. Executive Summary

2. Serum Gonadotrophin for Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Serum Gonadotrophin for Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Serum Gonadotrophin for Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Serum Gonadotrophin for Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Serum Gonadotrophin for Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Serum Gonadotrophin for Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Serum Gonadotrophin for Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Serum Gonadotrophin for Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Serum Gonadotrophin for Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Serum Gonadotrophin for Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Serum Gonadotrophin for Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Serum Gonadotrophin for Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Serum Gonadotrophin for Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Serum Gonadotrophin for Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Serum Gonadotrophin for Injection Market Competition by Key Manufacturers

9.1. Global Serum Gonadotrophin for Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Serum Gonadotrophin for Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. MSD Animal Health

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Ceva Santé Animale

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Syntex SA

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bioveta

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Ningbo Sansheng Biological Technology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ningbo Second Hormone Factory

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Chifeng Bo-en Pharmaceutical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Guangzhou Vbio-Pharma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. JALLY

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Ningbo Creator Animal Pharmaceutical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Serum Gonadotrophin for Injection Market

Figure 4: Global Serum Gonadotrophin for Injection Market: Drivers

Figure 5: Global Serum Gonadotrophin for Injection Market: Challenges

Figure 6: Global Serum Gonadotrophin for Injection Market: Trends

Figure 7: Global Serum Gonadotrophin for Injection Market: Opportunity

Figure 8: Global Serum Gonadotrophin for Injection Market: Restraint

Figure 9: Global Serum Gonadotrophin for Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Serum Gonadotrophin for Injection Market Value (USD Million) By Region

Figure 19: Global Serum Gonadotrophin for Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Serum Gonadotrophin for Injection Market Value (USD Million) By Region

Figure 27: Global Serum Gonadotrophin for Injection Market Share (%) By: Regions (2032)

Figure 28: Global Serum Gonadotrophin for Injection Market Volume (K) By Region

Figure 29: Global Serum Gonadotrophin for Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Serum Gonadotrophin for Injection Market Value (USD Million) By Region

Figure 37: Global Serum Gonadotrophin for Injection Market Share (%) By: Regions (2032)

Figure 38: Global Serum Gonadotrophin for Injection Market Volume (K) By Region

Figure 39: Global Serum Gonadotrophin for Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Serum Gonadotrophin for Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Serum Gonadotrophin for Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Serum Gonadotrophin for Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Serum Gonadotrophin for Injection Market Value (USD Million) By Region

Table 14: Global Serum Gonadotrophin for Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Serum Gonadotrophin for Injection Market Volume (K) By Region

Table 31: Global Serum Gonadotrophin for Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Serum Gonadotrophin for Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Serum Gonadotrophin for Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Serum Gonadotrophin for Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: MSD Animal Health Basic Information And Sales Area

Table 52: MSD Animal Health. Products Portfolio

Table 53: Ceva Santé Animale Basic Information And Sales Area

Table 54: Ceva Santé Animale. Products Portfolio

Table 55: Syntex SA Basic Information And Sales Area

Table 56: Syntex SA. Products Portfolio

Table 57: Bioveta Basic Information And Sales Area

Table 58: Bioveta. Products Portfolio

Table 59: Ningbo Sansheng Biological Technology Basic Information And Sales Area

Table 60: Ningbo Sansheng Biological Technology. Products Portfolio

Table 61: Ningbo Second Hormone Factory Basic Information And Sales Area

Table 62: Ningbo Second Hormone Factory. Products Portfolio

Table 63: Chifeng Bo-en Pharmaceutical Basic Information And Sales Area

Table 64: Chifeng Bo-en Pharmaceutical. Products Portfolio

Table 65: Guangzhou Vbio-Pharma Basic Information And Sales Area

Table 66: Guangzhou Vbio-Pharma. Products Portfolio

Table 67: JALLY Basic Information And Sales Area

Table 68: JALLY. Products Portfolio

Table 69: Ningbo Creator Animal Pharmaceutical Basic Information And Sales Area

Table 70: Ningbo Creator Animal Pharmaceutical. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Serum Gonadotrophin for Injection Market Value (USD Million) By Region

Table 80: Global Serum Gonadotrophin for Injection Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Serum Gonadotrophin for Injection Market Volume (K) By Region

Table 97: Global Serum Gonadotrophin for Injection Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Serum Gonadotrophin for Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	269.00 million
Revenue forecast in 2033	469.15 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MSD Animal Health; Ceva Santé Animale; Syntex SA; Bioveta; Ningbo Sansheng Biological Technology; Ningbo Second Hormone Factory; Chifeng Bo-en Pharmaceutical; Guangzhou Vbio-Pharma; JALLY; Ningbo Creator Animal Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Accelerated R&D in biologics and partnerships between key players to enhance formulation efficacy are expanding therapeutic applications, including oncology and endocrinology.

Restraints2 items

High treatment costs and stringent regulatory requirements for biological drugs are limiting market accessibility, particularly in emerging economies with fragmented reimbursement systems.

Stringent quality control for raw material sourcing and complex manufacturing processes are increasing production costs, compressing margins for mid-tier suppliers.

Opportunities2 items

Expansion into Asia-Pacific and Latin America, where rising awareness of reproductive health and improving healthcare spending are unlocking untapped patient pools.

Development of subcutaneous delivery systems and extended-release formulations could differentiate offerings in a competitive market, enhancing patient compliance and therapeutic outcomes.

Challenges2 items

Supply chain vulnerabilities, including geopolitical trade tensions and dependency on single-source suppliers, pose risks to consistent product availability.

Emergence of biosimilars and generic competitors is intensifying price pressures, requiring innovation or value-based differentiation to retain market share.

Market Segmentation

Loading chart…

Serum Gonadotrophin for Injection Segmentation Breakdown10 items

Application

Pig

Cattle

Sheep

Horse

Other Animals

Types

1000 IU/Unit

5000 IU/Unit

Others

Regional Insights

Loading chart…

Competitive Landscape

MSD Animal Health: Premium pricing, advanced veterinary formulation R&D

Ceva Santé Animale: Regional expansion in Asia-Pacific via OEM tie-ups

Syntex SA: Vertical integration for cost advantages in Latin American markets

Bioveta: Niche positioning in companion animal markets with customized dosing

Ningbo Sansheng Biological Technology: Cost leadership through localized manufacturing

Guangzhou Vbio-Pharma: Regulatory compliance expansion targeting EU/US markets

Key Serum Gonadotrophin for Injection Companies10 items

MSD Animal Health

Ceva Santé Animale

Syntex SA

Bioveta

Ningbo Sansheng Biological Technology

Ningbo Second Hormone Factory

Chifeng Bo-en Pharmaceutical

Guangzhou Vbio-Pharma

JALLY

Ningbo Creator Animal Pharmaceutical

Market Ecosystem

Raw material suppliers – provide human-derived or recombinant hormones for serum production

OEMs/Manufacturers – produce sterile injectable formulations using validated biopharmaceutical processes

Technology providers – develop specialized extraction and purification systems for hormone isolation

Distributors/Channel partners – manage temperature-controlled logistics to healthcare facilities

Healthcare providers – administer treatments in fertility clinics and hospitals

Regulators/Standards bodies – enforce quality control and approval protocols for market access

Service providers – offer storage solutions and post-distribution monitoring for drug stability

Recent Industry Insights

Analyst Overview

Key Insights3 items

Innovation landscape emphasizes cost-effective biosimilars and patient-centric delivery solutions.

Demand-supply balance remains stable in developed regions but faces strain in Asia-Pacific due to scalability challenges.

Top risks include regulatory scrutiny, patent expirations, and fluctuating raw material prices.

Table of Contents